These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 32076885)

  • 41. Design and evaluation of a specific, bi-phase extended release system based on differently coated mini-tablets.
    Aleksovski A; Luštrik M; Šibanc R; Dreu R
    Eur J Pharm Sci; 2015 Jul; 75():114-22. PubMed ID: 25845632
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Formulation and pharmacokinetics of colon-specific double-compression coated mini-tablets: Chronopharmaceutical delivery of ketorolac tromethamine.
    Vemula SK
    Int J Pharm; 2015 Aug; 491(1-2):35-41. PubMed ID: 26056929
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In vitro controlled release of alfuzosin hydrochloride using HPMC-based matrix tablets and its comparison with marketed product.
    Nair A; Gupta R; Vasanti S
    Pharm Dev Technol; 2007; 12(6):621-5. PubMed ID: 18161635
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In vivo and in vitro evaluation of three controlled release principles of 6-N-cyclohexyl-2'-O-methyladenosine.
    Royce A; Li S; Weaver M; Shah U
    J Control Release; 2004 May; 97(1):79-90. PubMed ID: 15147806
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Preparation and evaluation of once-daily sustained-release coated tablets of tolterodine-L-tartrate.
    Pradhan R; Kim YI; Chang SW; Kim JO
    Int J Pharm; 2014 Jan; 460(1-2):205-11. PubMed ID: 24184032
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Formulation development of sustained-release hydrophilic matrix tablets of zileuton.
    Qiu Y; Hui HW; Cheskin H
    Pharm Dev Technol; 1997 Aug; 2(3):197-204. PubMed ID: 9552447
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In vitro and in vivo evaluation of controlled-release matrix tablets of highly water-soluble drug applying different mw polyethylene oxides (PEO) as retardants.
    Wen H; Li X; Li Y; Wang H; Wang Y; Wang T; Pan W; Yang X
    Drug Dev Ind Pharm; 2018 Apr; 44(4):544-552. PubMed ID: 29130753
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Modulation of microenvironmental pH for dual release and reduced in vivo gastrointestinal bleeding of aceclofenac using hydroxypropyl methylcellulose-based bilayered matrix tablet.
    Kang WH; Nguyen HV; Park C; Choi YW; Lee BJ
    Eur J Pharm Sci; 2017 May; 102():85-93. PubMed ID: 28263912
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The influence of thermal treatment and type of insoluble poly(meth)acrylates on dissolution behavior of very soluble drug from hypromellose matrix tablets evaluated by multivariate data analysis.
    Kubova K; Peček D; Hasserová K; Doležel P; Pavelková M; Vyslouzil J; Muselík J; Vetchy D
    Pharm Dev Technol; 2017 Mar; 22(2):206-217. PubMed ID: 28058866
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Use of hydrophilic natural gums in formulation of sustained-release matrix tablets of tramadol hydrochloride.
    Varshosaz J; Tavakoli N; Kheirolahi F
    AAPS PharmSciTech; 2006 Mar; 7(1):E24. PubMed ID: 16584155
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Water soluble cellulose acetate: a versatile polymer for film coating.
    Wheatley TA
    Drug Dev Ind Pharm; 2007 Mar; 33(3):281-90. PubMed ID: 17454061
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Design and in vitro evaluation of zidovudine oral controlled release tablets prepared using hydroxypropyl methylcellulose.
    Ravi PR; Ganga S; Saha RN
    Chem Pharm Bull (Tokyo); 2008 Apr; 56(4):518-24. PubMed ID: 18379101
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Advanced formulation design of venlafaxine hydrochloride coated and triple-layer tablets containing hypromellose.
    Gohel M; Bariya SH
    Pharm Dev Technol; 2009; 14(6):650-8. PubMed ID: 19883254
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of injection moulding as a pharmaceutical technology to produce matrix tablets.
    Quinten T; De Beer T; Vervaet C; Remon JP
    Eur J Pharm Biopharm; 2009 Jan; 71(1):145-54. PubMed ID: 18511248
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The impact of polymers on 3D microstructure and controlled release of sildenafil citrate from hydrophilic matrices.
    Krupa A; Tabor Z; Tarasiuk J; Strach B; Pociecha K; Wyska E; Wroński S; Łyszczarz E; Jachowicz R
    Eur J Pharm Sci; 2018 Jul; 119():234-243. PubMed ID: 29679708
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Novel extended in vitro-in vivo correlation model for the development of extended-release formulations for baclofen: From formulation composition to in vivo pharmacokinetics.
    Kim TH; Bulitta JB; Kim DH; Shin S; Shin BS
    Int J Pharm; 2019 Feb; 556():276-286. PubMed ID: 30543888
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Non-uniform drug distribution matrix system (NUDDMat) for zero-order release of drugs with different solubility.
    Cerea M; Foppoli A; Palugan L; Melocchi A; Zema L; Maroni A; Gazzaniga A
    Int J Pharm; 2020 May; 581():119217. PubMed ID: 32165228
    [TBL] [Abstract][Full Text] [Related]  

  • 58.
    Vrettos NN; Wang P; Zhou Y; Roberts CJ; Xu J; Yao H; Zhu Z
    Pharm Dev Technol; 2021 Mar; 26(3):349-361. PubMed ID: 33430679
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The performance of HPMC matrix tablets using various agglomeration manufacturing processes.
    Košir D; Vrečer F
    Drug Dev Ind Pharm; 2017 Feb; 43(2):329-337. PubMed ID: 27739880
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In vitro/in vivo evaluation of two series of TA-5707F controlled release matrix tablets prepared with hydroxypropyl methyl cellulose derivatives with entero-soluble or gel-formation properties.
    Yamakita H; Maejima T; Osawa T
    Biol Pharm Bull; 1995 Oct; 18(10):1409-16. PubMed ID: 8593447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.